DOI: 10.1097/01.NT.0000357558.72340.26

,  

Issn Print: 1533-7006

Publication Date: 2009/07/02


Print

New Safety Data Reported on Natalizumab for MS and PML Risk

ALICE GOODMAN

    loading  Checking for direct PDF access through Ovid

Excerpt

Data from the manufacturer of natalizumab suggest that better monitoring and clinical vigilance for progressive multiple leukoencephalopathy (PML) has led to improved clinical outcomes for MS patients who develop PML.

Related Topics

    loading  Loading Related Articles